Atarax (hydroxyzine) received FDA approval on December 14, 1956 [1].
When was Atarax first approved by the FDA?
Atarax, containing the active ingredient hydroxyzine, was approved by the U.S. Food and Drug Administration (FDA) on December 14, 1956 [1]. This approval marked its entry into the pharmaceutical market for treating anxiety and itching [2].
What is hydroxyzine used for?
Hydroxyzine, marketed as Atarax and other brand names, is primarily used to treat anxiety symptoms and to relieve itching associated with allergic reactions [2]. It is also sometimes prescribed for nausea and vomiting [3]. The medication works by affecting the central nervous system and histamine receptors [3].
What other forms of hydroxyzine are available?
Besides Atarax, hydroxyzine is available under other brand names, such as Vistaril, which is typically used for anxiety and tension associated with psychoneurotic conditions and as an adjunct to antihistamines in management of pruritus [4]. Vistaril is also indicated for the use of anxiety and tension in patients with coronary artery disease and patients in the immediate preoperative period whose anxiety and tension by the surgical approach may reasonably be expected to prolong the period of recovery [4].
How does Atarax work?
Hydroxyzine is an antihistamine and an antiemetic. It functions by blocking the action of histamine, a substance in the body that causes allergic symptoms. It also has mild tranquilizing effects, which help to reduce anxiety [3].
When does the patent for Atarax expire?
Information on the specific patent expiry dates for Atarax is best accessed through specialized databases. DrugPatentWatch.com provides detailed patent information for pharmaceuticals [5].
Who manufactures Atarax?
The manufacturing and marketing of Atarax and its generic forms have been handled by various pharmaceutical companies over time. Historically, UCB Pharma was associated with the Atarax brand [6].
What are the side effects of Atarax?
Common side effects of Atarax can include drowsiness, dry mouth, and dizziness. Less common side effects may involve blurred vision, constipation, and headaches [3]. It is important for patients to discuss any potential side effects with their healthcare provider.
Are there alternatives to Atarax for anxiety or itching?
For anxiety, alternative treatments may include other classes of medications such as selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines, as well as psychotherapy. For itching, topical corticosteroids, oral antihistamines, or other dermatological treatments may be considered, depending on the cause and severity of the condition [3][7].
Can Atarax be used during pregnancy?
The use of Atarax during pregnancy should be carefully considered, as it may pose risks. Pregnant individuals should consult with their healthcare provider to weigh the potential benefits against the risks before taking this medication [3].
What is the difference between Atarax and Vistaril?
Both Atarax and Vistaril contain hydroxyzine, but they are often indicated for different primary uses and may have slight differences in formulation or recommended dosages. Atarax is commonly prescribed for anxiety and itching, while Vistaril is also used for anxiety, particularly in specific clinical contexts like pre-operative patients or those with coronary artery disease [2][4].
What are the regulatory considerations for hydroxyzine?
As an approved medication, hydroxyzine is subject to ongoing regulatory oversight by the FDA. This includes monitoring for safety, efficacy, and manufacturing quality. Prescribing information and patient labeling are updated as new data becomes available [1][3].
Sources:
[1] https://www.fda.gov/drugs/development-approval-process/drug-approvals-and-databases
[2] https://www.webmd.com/drugs/2/drug-1598/atarax-oral/details
[3] https://medlineplus.gov/druginfo/meds/a681420.html
[4] https://www.rxlist.com/vistaril-drug.htm
[5] https://drugpatentwatch.com/
[6] https://www.drugs.com/atarax.html
[7] https://www.mayoclinic.org/diseases-conditions/anxiety/diagnosis-treatment/drc-20350967